Pay in 4 interest-free payments of $7.02 Learn more
Ships within 48 hours · Estimated delivery Sep 2 - Sep 7
OASIS trials: establishing effective doses Phase 2 OASIS 1 findings: Tested multiple dose levels: 0.3mg, 0.6mg, 1.2mg, 2.4mg, 4.5mg weekly Duration: 26 weeks Primary endpoint: Weight loss at each dose Dose-response results: 0.3mg weekly: ~4% body weight loss 0.6mg weekly: ~6% body weight loss 1.2mg weekly: ~8% body weight loss 2.4mg weekly: ~10% body weight loss 4.5mg weekly: ~12% body weight loss Key insight: Clear dose-response relationship
The FDAs 2025 advertising-claim enforcement push against telehealth marketing of compounded GLP-1 drugs is a useful precedent
It is capital
Specifically, the relentless wear-and-tear from reactive oxygen species (ROS) and chronic low-grade inflammation
US$ 22.66
US$ 28.27
US$ 26.28
US$ 20.42
US$ 23.85
US$ 27.65
US$ 27.23
US$ 23.19
US$ 22.60
US$ 24.91
